Investment objective

To provide long-term capital growth by investing primarily in equity securities of U.S. companies whose businesses relate to life sciences and technology and are expected to benefit from scientific and technological advances.

  • Fund Category U.S. Equity Funds
  • Inception Date Aug 13, 2001
Download fund details    Download fund commentary   

Fund details

Series
Currency
Fund code
MER * (%)
F CAD 35070 0.94%

Portfolio analysis As of Feb 28, 2026

98% 2%
Equity Fixed Income

Asset mix

Equity Sector Allocation
Information Technology57.5%
Health Care19.8%
Communication Services19.6%
Industrials1.1%
Consumer Discretionary0.8%
Financials0.7%
Real Estate0.4%
Top 10 Holdings
% Assets
Alphabet Inc - Class A Shares 11.0%
NVIDIA Corp 9.9%
Apple Inc 9.2%
Microsoft Corp 7.8%
Meta Platforms Inc - Class A Shares 5.0%
Broadcom Inc 4.7%
Eli Lilly & Co 3.2%
Johnson & Johnson 2.2%
Micron Technology Inc 1.8%
Netflix Inc 1.6%
Total % of Top 10 Holdings 56.4%

Geographic allocation

Region

Performance analysis

Growth of $10,000 since inception

Calendar returns

Trailing return

1 Mth 3 Mth 6 Mth 1 year 3 years 5 years 10 years Since Inception
-2.5 -5.8 6.6 12.6 27.2 16.1 18.6 8.7 Fund

Distribution ($)/unit

YTD* 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016
Total distributions --- --- --- --- --- --- --- --- --- --- ---
Interest --- --- --- --- --- --- --- --- --- --- ---
Canadian dividends --- --- --- --- --- --- --- --- --- --- ---
Foreign dividends --- --- --- --- --- --- --- --- --- --- ---
Foreign taxes paid --- --- --- --- --- --- --- --- --- --- ---
Capital gains --- --- --- --- --- --- --- --- --- --- ---
Return of capital --- --- --- --- --- --- --- --- --- --- ---

* MER (%) is based on actual expenses for the preceding calendar year or most recent half-year period ended June 30 expressed on an annualized basis, depending on availability of date at the time of publication.